As GLP-1 based therapies are increasingly prescribed to patients with type-2 diabetes, many of whom also have significant coronary artery disease, it will be important to continue careful surveillance to assess whether these patients are provided some degree of protection should they experience an ischaemic cardiac event. This evidence concerns the gene GCG and coronary artery disorder.